Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

DSM - Repurchase of Shares (19 - 22 March 2018)

Royal DSM
Posted on: 23 Mar 18
DSM - Repurchase of Shares (19 - 22 March 2018)

PR Newswire

HEERLEN, the Netherlands, March 23, 2018

HEERLEN, the Netherlands, March 23, 2018 /PRNewswire/ --

Royal DSM, a global science-based company active in health, nutrition and materials , has repurchased 136 , 6 50 of it s own shares in the period from 19 March 201 8 up to and including 2 2 March 2018 at an average price of 80.59 . This is in accordance with the repurchase , covering commitments under share based compensation plans and for stock dividend s , announced on 1 9 March 2018 . The consideration of this repurchase was 1 1.0 million. 

     (Logo: https://mma.prnewswire.com/media/657851/DSM_Logo.jpg )

For more detailed information see the 'Daily transaction details 1.6m Share Repurchase Program announced 19 Mar 2018'.

DSM - Bright Science. Brighter Living.™ 

Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in life sciences and materials sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM and its associated companies deliver annual net sales of about €10 billion with approximately 25,000 employees. The company is listed on Euronext Amsterdam. More information can be found at http://www.dsm.com.

Forward Looking Statement  

This press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law.

For more information:
DSM Media Relations
Lieke de Jong
tel. +31(0)45-578-2421        
e-mail media.contacts@dsm.com

DSM Investor Relations
Dave Huizing
tel. +31(0)45-5782864
e-mail investor.relations@dsm.com

    PRN NLD

PR Newswire
www.prnewswire.com

Last updated on: 23/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.